• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用全基因组综合分析检测常见 B 细胞淋巴肿瘤的新驱动基因。

Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.

机构信息

Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Galicia, Spain.

Department of Hematology, Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Galicia, Spain.

出版信息

PLoS One. 2021 May 4;16(5):e0248886. doi: 10.1371/journal.pone.0248886. eCollection 2021.

DOI:10.1371/journal.pone.0248886
PMID:33945543
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8096002/
Abstract

B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregation of diverse tumors in pan-cancer genomic studies has become a useful tool to detect new driver genes, while enabling the comparison of mutational patterns across tumors. Here we present an integrated analysis of 354 B-cell lymphoid disorders. 112 recurrently mutated genes were discovered, of which KMT2D, CREBBP, IGLL5 and BCL2 were the most frequent, and 31 genes were putative new drivers. Mutations in CREBBP, TNFRSF14 and KMT2D predominated in follicular lymphoma, whereas those in BTG2, HTA-A and PIM1 were more frequent in diffuse large B-cell lymphoma. Additionally, we discovered 31 significantly mutated protein networks, reinforcing the role of genes such as CREBBP, EEF1A1, STAT6, GNA13 and TP53, but also pointing towards a myriad of infrequent players in lymphomagenesis. Finally, we report aberrant expression of oncogenes and tumor suppressors associated with novel noncoding mutations (DTX1 and S1PR2), and new recurrent copy number aberrations affecting immune check-point regulators (CD83, PVR) and B-cell specific genes (TNFRSF13C). Our analysis expands the number of mutational drivers of B-cell lymphoid neoplasms, and identifies several differential somatic events between disease subtypes.

摘要

B 细胞淋巴增生性疾病表现出多种诊断实体,具有异质的行为。多项努力集中在确定 B 细胞淋巴瘤亚型的基因组驱动因素上。与此同时,在泛癌基因组研究中聚集不同的肿瘤已成为检测新驱动基因的有用工具,同时能够比较肿瘤之间的突变模式。在这里,我们对 354 种 B 细胞淋巴样疾病进行了综合分析。发现了 112 个经常突变的基因,其中 KMT2D、CREBBP、IGLL5 和 BCL2 最为常见,有 31 个基因是潜在的新驱动基因。CREBBP、TNFRSF14 和 KMT2D 的突变在滤泡性淋巴瘤中占主导地位,而 BTG2、HTA-A 和 PIM1 的突变在弥漫性大 B 细胞淋巴瘤中更为常见。此外,我们还发现了 31 个显著突变的蛋白质网络,这加强了 CREBBP、EEF1A1、STAT6、GNA13 和 TP53 等基因的作用,但也指出了淋巴发生过程中有无数罕见的参与者。最后,我们报告了与新型非编码突变(DTX1 和 S1PR2)相关的癌基因和肿瘤抑制基因的异常表达,以及影响免疫检查点调节剂(CD83、PVR)和 B 细胞特异性基因(TNFRSF13C)的新的反复出现的拷贝数异常。我们的分析扩展了 B 细胞淋巴样肿瘤的突变驱动基因数量,并确定了疾病亚型之间的几个差异体细胞事件。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/88a57cfca228/pone.0248886.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/7de5a5bdb5c9/pone.0248886.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/9141bdb933f1/pone.0248886.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/a80c14057098/pone.0248886.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/88a57cfca228/pone.0248886.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/7de5a5bdb5c9/pone.0248886.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/9141bdb933f1/pone.0248886.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/a80c14057098/pone.0248886.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3a8/8096002/88a57cfca228/pone.0248886.g004.jpg

相似文献

1
Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes.利用全基因组综合分析检测常见 B 细胞淋巴肿瘤的新驱动基因。
PLoS One. 2021 May 4;16(5):e0248886. doi: 10.1371/journal.pone.0248886. eCollection 2021.
2
Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.具有CD23表达、1p36/TNFRSF14异常和STAT6突变的t(14;18)阴性结内弥漫性滤泡性淋巴瘤变体的特征分析
Mod Pathol. 2016 Jun;29(6):570-81. doi: 10.1038/modpathol.2016.51. Epub 2016 Mar 11.
3
Targeted next generation sequencing reveals high mutation frequency of and in high-grade B-cell lymphoma with and and/or rearrangements.靶向二代测序揭示了伴有和重排以及和/或重排的高级别B细胞淋巴瘤中及的高突变频率。
Haematologica. 2019 Apr;104(4):e154-e157. doi: 10.3324/haematol.2018.198572. Epub 2018 Oct 11.
4
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.连接组蛋白基因 HIST1H1B、C、D 和 E;OCT2(POU2F2);IRF8 和 ARID1A 的突变是滤泡性淋巴瘤发病机制的基础。
Blood. 2014 Mar 6;123(10):1487-98. doi: 10.1182/blood-2013-05-500264. Epub 2014 Jan 16.
5
Inactivating mutations of acetyltransferase genes in B-cell lymphoma.B 细胞淋巴瘤中乙酰转移酶基因的失活突变。
Nature. 2011 Mar 10;471(7337):189-95. doi: 10.1038/nature09730.
6
Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传亚型简化算法。
Signal Transduct Target Ther. 2023 Apr 10;8(1):145. doi: 10.1038/s41392-023-01358-y.
7
Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia.BCL-6突变在整个B细胞肿瘤谱系中的分布与模式。
Blood. 2000 Jan 15;95(2):651-9.
8
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.采用全基因组测序对弥漫性大 B 细胞淋巴瘤进行突变和结构分析。
Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.
9
New developments in non-Hodgkin lymphoid malignancies.非霍奇金淋巴瘤的新进展。
Pathology. 2021 Apr;53(3):349-366. doi: 10.1016/j.pathol.2021.01.002. Epub 2021 Mar 5.
10
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.ATM突变与弥漫性大B细胞淋巴瘤中ARF-TP53肿瘤抑制通路的失活相关。
Blood. 2002 Aug 15;100(4):1430-7. doi: 10.1182/blood-2002-02-0382.

引用本文的文献

1
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data.基于基因测序数据的促增殖和抗凋亡特征量化的患者特异性计算模型可预测 B 细胞淋巴瘤的预后。
Blood Cancer J. 2024 Jul 4;14(1):105. doi: 10.1038/s41408-024-01090-y.
2
B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells.B 细胞受体信号转导及其他:Igα(CD79a)/Igβ(CD79b)在正常和恶性 B 细胞中的作用。
Int J Mol Sci. 2023 Dec 19;25(1):10. doi: 10.3390/ijms25010010.
3
Single-cell biological network inference using a heterogeneous graph transformer.

本文引用的文献

1
A practical framework and online tool for mutational signature analyses show inter-tissue variation and driver dependencies.一个用于突变特征分析的实用框架和在线工具显示了组织间的变异和驱动依赖性。
Nat Cancer. 2020 Feb;1(2):249-263. doi: 10.1038/s43018-020-0027-5. Epub 2020 Feb 17.
2
SIRPB1 promotes prostate cancer cell proliferation via Akt activation.SIRPB1 通过激活 Akt 促进前列腺癌细胞增殖。
Prostate. 2020 Mar;80(4):352-364. doi: 10.1002/pros.23950. Epub 2020 Jan 6.
3
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.
基于异质图 Transformer 的单细胞生物网络推断
Nat Commun. 2023 Feb 21;14(1):964. doi: 10.1038/s41467-023-36559-0.
4
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.经典霍奇金淋巴瘤的分子进化:霍奇金和里斯汀细胞全基因组测序的启示。
Blood Cancer Discov. 2023 May 1;4(3):208-227. doi: 10.1158/2643-3230.BCD-22-0128.
5
Comprehensive analysis of prognostic value, relationship to cell cycle, immune infiltration and m6A modification of ZSCAN20 in hepatocellular carcinoma.全面分析 ZSCAN20 在肝细胞癌中的预后价值、与细胞周期的关系、免疫浸润和 m6A 修饰。
Aging (Albany NY). 2022 Dec 3;14(23):9550-9578. doi: 10.18632/aging.204312.
6
ATR-mediated DNA damage responses underlie aberrant B cell activity in systemic lupus erythematosus.ATR 介导的 DNA 损伤反应是红斑狼疮患者 B 细胞活性异常的基础。
Sci Adv. 2022 Oct 28;8(43):eabo5840. doi: 10.1126/sciadv.abo5840.
7
Circulating Tumor DNA Characteristics Based on Next Generation Sequencing and Its Correlation With Clinical Parameters in Patients With Lymphoma.基于下一代测序的淋巴瘤患者循环肿瘤DNA特征及其与临床参数的相关性
Front Oncol. 2022 Jul 5;12:901547. doi: 10.3389/fonc.2022.901547. eCollection 2022.
8
Sphingolipids and Lymphomas: A Double-Edged Sword.鞘脂与淋巴瘤:一把双刃剑
Cancers (Basel). 2022 Apr 19;14(9):2051. doi: 10.3390/cancers14092051.
9
The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma.结外NK/T细胞淋巴瘤的病理及遗传学特征
Life (Basel). 2022 Jan 5;12(1):73. doi: 10.3390/life12010073.
10
Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma.肾透明细胞癌和肾乳头状细胞癌肿瘤微环境中免疫相关基因的综合分析
Front Mol Biosci. 2021 Nov 23;8:760031. doi: 10.3389/fmolb.2021.760031. eCollection 2021.
靶向TIGIT-PVR免疫检查点轴作为乳腺癌的新型治疗选择。
Oncoimmunology. 2019 Oct 12;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605. eCollection 2019.
4
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.IRF4 重排的大 B 细胞淋巴瘤的独特分子特征。
Blood. 2020 Jan 23;135(4):274-286. doi: 10.1182/blood.2019002699.
5
Pan-cancer whole-genome analyses of metastatic solid tumours.泛癌种实体瘤全基因组分析。
Nature. 2019 Nov;575(7781):210-216. doi: 10.1038/s41586-019-1689-y. Epub 2019 Oct 23.
6
The whole-genome landscape of Burkitt lymphoma subtypes.弥漫性大 B 细胞淋巴瘤亚型的全基因组图谱。
Blood. 2019 Nov 7;134(19):1598-1607. doi: 10.1182/blood.2019001880.
7
Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling.HGAL 和 Grb2 蛋白之间的相互作用调节 B 细胞受体信号转导。
Blood Adv. 2019 Aug 13;3(15):2286-2297. doi: 10.1182/bloodadvances.2018016162.
8
CD81 is a novel immunotherapeutic target for B cell lymphoma.CD81 是 B 细胞淋巴瘤的一种新型免疫治疗靶点。
J Exp Med. 2019 Jul 1;216(7):1497-1508. doi: 10.1084/jem.20190186. Epub 2019 May 23.
9
WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs.WebGestalt 2019:基因集分析工具包,具有全新的用户界面和 API。
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205. doi: 10.1093/nar/gkz401.
10
Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma.散发性伯基特淋巴瘤发病机制中的基因组和转录组变化相辅相成。
Nat Commun. 2019 Mar 29;10(1):1459. doi: 10.1038/s41467-019-08578-3.